AMLX

MKT CAP:$1B

Amylyx Pharmaceuticals, Inc.

Market Cap

$1B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$17.32+$5.90 (+51.66%)

Apr 23, 2026

Company Details

Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX00...

CEO

Joshua Cohen

IPO Date

Jan 7, 2022

Website

amylyx.com

Key Metrics TTM

Revenue

$0

-100.0% YoY

Net Income

-$145M

EPS (Diluted)

-$1.53

Free Cash Flow

-$123M

Revenue / Share

$0.00

Gross Margin

—

Operating Margin

—

Net Margin

—

FCF Margin

—

P/S

—

P/E

—

Earnings Reports

Q1 2026

May 14, 2026

PENDING

FY 2025

Mar 3, 2026

$0-100.0%EPS -$1.53

Q4 2025

Mar 3, 2026

$0+100.0%EPS -$0.28

Q3 2025

Nov 6, 2025

$0-100.0%EPS -$0.37

Q2 2025

Aug 7, 2025

$0+100.0%EPS -$0.46

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$0	$0	-$48M
Q2 22	$0	$0	-$54M
Q3 22	$345.0K	$173.0K	-$55M
Q4 22	$22M	$19M	-$45M
Q1 23	$71M	$66M	-$2M
Q2 23	$98M	$93M	$20M
Q3 23	$103M	$97M	$19M
Q4 23	$108M	$99M	$2M
Q1 24	$89M	-$28M	-$122M
Q2 24	-$1M	-$9M	-$53M
Q3 24	$416.0K	-$393.0K	-$76M
Q4 24	-$665.0K	-$665.0K	-$41M
Q1 25	$0	$0	-$38M
Q2 25	$0	-$141.0K	-$43M
Q3 25	$0	-$20M	-$36M
Q4 25	$0	-$108.0K	-$37M

Valuation

Quarter	P/S	P/E
Q1 22	—	—
Q2 22	—	—
Q3 22	4117.7x	—
Q4 22	63.9x	—
Q1 23	15.2x	—
Q2 23	7.4x	—
Q3 23	4.8x	773.8x
Q4 23	3.7x	28.8x
Q1 24	3.6x	—
Q2 24	4.8x	—
Q3 24	7.2x	—
Q4 24	16.3x	—
Q1 25	—	—
Q2 25	—	—
Q3 25	—	—
Q4 25	—	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	-$41M	-$41M
Q2 22	-$46M	-$48M
Q3 22	-$43M	-$44M
Q4 22	-$50M	-$50M
Q1 23	-$5M	-$5M
Q2 23	$9M	$8M
Q3 23	-$5M	-$6M
Q4 23	$14M	$13M
Q1 24	-$489.0K	-$556.0K
Q2 24	-$67M	-$67M
Q3 24	-$42M	-$42M
Q4 24	-$59M	-$59M
Q1 25	-$40M	-$40M
Q2 25	-$25M	-$25M
Q3 25	-$30M	-$30M
Q4 25	-$28M	-$28M

Capital Expenditures

Quarter	CapEx
Q1 22	$342.0K
Q2 22	$1M
Q3 22	$459.0K
Q4 22	$620.0K
Q1 23	$250.0K
Q2 23	$278.0K
Q3 23	$357.0K
Q4 23	$356.0K
Q1 24	$67.0K
Q2 24	$89.0K
Q3 24	$19.0K
Q4 24	$20.0K
Q1 25	$11.0K
Q2 25	$17.0K
Q3 25	$24.0K
Q4 25	$86.0K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	—	+271.6%
Q2 22	—	+191.9%
Q3 22	—	+140.1%
Q4 22	—	+134.8%
Q1 23	—	+53.7%
Q2 23	—	+43.8%
Q3 23	+29666.1%	+52.6%
Q4 23	+395.5%	+60.2%
Q1 24	+24.1%	+186.8%
Q2 24	-101.0%	-32.8%
Q3 24	-99.6%	-9.4%
Q4 24	-100.6%	-62.5%
Q1 25	-100.0%	-82.1%
Q2 25	+100.0%	-18.2%
Q3 25	-100.0%	-52.6%
Q4 25	+100.0%	-8.5%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$4M	—
Q2 22	$6M	—
Q3 22	$6M	1601.2%
Q4 22	$6M	27.8%
Q1 23	$8M	10.5%
Q2 23	$10M	10.1%
Q3 23	$10M	9.9%
Q4 23	$10M	8.8%
Q1 24	$10M	11.2%
Q2 24	$10M	—
Q3 24	$7M	1635.3%
Q4 24	$7M	—
Q1 25	$7M	—
Q2 25	$7M	—
Q3 25	$7M	—
Q4 25	$6M	—

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q1 22	$21M	$26M	—
Q2 22	$24M	$30M	—
Q3 22	$25M	—	$30M
Q4 22	$23M	$56M	—
Q1 23	$24M	$44M	—
Q2 23	$29M	—	$43M
Q3 23	$30M	—	$49M
Q4 23	$45M	—	$52M
Q1 24	$37M	—	$58M
Q2 24	$23M	—	$22M
Q3 24	$21M	—	$18M
Q4 24	$23M	—	$17M
Q1 25	$22M	—	$16M
Q2 25	$27M	—	$16M
Q3 25	$20M	—	$16M
Q4 25	$21M	—	$15M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$110M	$145M	$255M
Q2 22	$67M	$139M	$207M
Q3 22	$108M	$55M	$163M
Q4 22	$63M	$284M	$347M
Q1 23	$115M	$231M	$346M
Q2 23	$248M	$110M	$357M
Q3 23	$135M	$220M	$355M
Q4 23	$170M	$201M	$371M
Q1 24	$171M	$203M	$373M
Q2 24	$75M	$235M	$310M
Q3 24	$72M	$163M	$234M
Q4 24	$77M	$99M	$177M
Q1 25	$60M	$144M	$204M
Q2 25	$58M	$123M	$181M
Q3 25	$225M	$119M	$344M
Q4 25	$227M	$90M	$317M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	52M	-6.5%	+12.3%
Q2 22	58M	+12.9%	+26.8%
Q3 22	59M	+0.4%	+6.0%
Q4 22	65M	+11.8%	+18.5%
Q1 23	71M	+8.3%	+37.3%
Q2 23	70M	-1.0%	+20.3%
Q3 23	70M	-0.5%	+19.2%
Q4 23	69M	-0.8%	+5.8%
Q1 24	68M	-1.9%	-4.2%
Q2 24	68M	+0.3%	-3.0%
Q3 24	68M	+0.1%	-2.4%
Q4 24	69M	+0.7%	-0.9%
Q1 25	86M	+24.9%	+26.3%
Q2 25	89M	+4.0%	+31.0%
Q3 25	93M	+4.7%	+37.1%
Q4 25	95M	+1.3%	+37.9%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	$0	205
Q2 22	$0	205
Q3 22	$1.7K	205
Q4 22	$83.5K	262
Q1 23	$272.6K	262
Q2 23	$374.9K	262
Q3 23	$392.0K	262
Q4 23	$282.4K	384
Q1 24	$230.8K	384
Q2 24	-$2.7K	384
Q3 24	$1.1K	384
Q4 24	-$5.4K	123
Q1 25	$0	123
Q2 25	$0	123
Q3 25	$0	123
Q4 25	$0	160K

Revenue / Employee